Human islet allotransplantation with Basiliximab in type I diabetic patients with end-stage renal failure

Transplant Proc. 2002 May;34(3):823-5. doi: 10.1016/s0041-1345(01)02924-4.

Authors

J Oberholzer¹, C Toso, F Triponez, F Ris, P Bucher, A Demirag, J Lou, P Majno, L Buehler, J Philippe, P Morel

Affiliation

¹ Division of Surgical Research, Clinic of Digestive and Transplant Surgery, Department of Surgery, University Hospital of Geneva, Geneva, Switzerland. celtrans@cmu.unige.ch

PMID: 12034197
DOI: 10.1016/s0041-1345(01)02924-4

No abstract available

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Basiliximab
Blood Glucose / metabolism
C-Peptide / blood
Case-Control Studies
Diabetes Mellitus, Type 1 / surgery*
Diabetic Nephropathies / surgery*
Follow-Up Studies
Glycated Hemoglobin / metabolism
Graft Survival / physiology*
Humans
Immunosuppressive Agents / therapeutic use*
Islets of Langerhans Transplantation / immunology
Islets of Langerhans Transplantation / physiology*
Kidney Failure, Chronic / surgery*
Kidney Transplantation / immunology
Kidney Transplantation / physiology*
Recombinant Fusion Proteins*
Reoperation
Retrospective Studies
Time Factors
Transplantation, Homologous

Substances

Antibodies, Monoclonal
Blood Glucose
C-Peptide
Glycated Hemoglobin A
Immunosuppressive Agents
Recombinant Fusion Proteins
Basiliximab